X4 Pharmaceuticals, Inc. (NASDAQ:XFOR – Get Free Report) CEO Paula Ragan sold 76,473 shares of the firm’s stock in a transaction on Friday, January 24th. The stock was sold at an average price of $0.45, for a total value of $34,412.85. Following the completion of the sale, the chief executive officer now owns 1,087,386 shares of the company’s stock, valued at approximately $489,323.70. This represents a 6.57 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.
X4 Pharmaceuticals Price Performance
XFOR opened at $0.48 on Wednesday. The business’s 50-day moving average is $0.55 and its two-hundred day moving average is $0.61. X4 Pharmaceuticals, Inc. has a 1 year low of $0.26 and a 1 year high of $1.60. The company has a debt-to-equity ratio of 1.26, a current ratio of 4.89 and a quick ratio of 4.80. The firm has a market capitalization of $82.17 million, a PE ratio of -5.35 and a beta of 0.14.
Hedge Funds Weigh In On X4 Pharmaceuticals
Several institutional investors and hedge funds have recently added to or reduced their stakes in XFOR. Verition Fund Management LLC purchased a new position in X4 Pharmaceuticals in the third quarter valued at about $30,000. SG Americas Securities LLC purchased a new stake in shares of X4 Pharmaceuticals during the third quarter worth about $37,000. XTX Topco Ltd purchased a new stake in shares of X4 Pharmaceuticals during the second quarter worth about $65,000. Rhumbline Advisers grew its stake in shares of X4 Pharmaceuticals by 14.6% during the second quarter. Rhumbline Advisers now owns 187,246 shares of the company’s stock worth $109,000 after acquiring an additional 23,831 shares during the last quarter. Finally, Jane Street Group LLC grew its stake in shares of X4 Pharmaceuticals by 103.4% during the third quarter. Jane Street Group LLC now owns 248,447 shares of the company’s stock worth $166,000 after acquiring an additional 126,296 shares during the last quarter. Hedge funds and other institutional investors own 72.03% of the company’s stock.
Analysts Set New Price Targets
Check Out Our Latest Report on X4 Pharmaceuticals
X4 Pharmaceuticals Company Profile
X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.
Featured Articles
- Five stocks we like better than X4 Pharmaceuticals
- What Are Treasury Bonds?
- Survey Reveals: Top 150 Best Coffee Shops for Remote Workers and Business Deals [2025]
- EV Stocks and How to Profit from Them
- What Does the Future Hold for Eli Lilly?
- How to Start Investing in Real Estate
- Oracle Stock Drops Nearly 14% – Is Now the Time to Buy?
Receive News & Ratings for X4 Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for X4 Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.